0001209191-22-042211.txt : 20220714 0001209191-22-042211.hdr.sgml : 20220714 20220714213350 ACCESSION NUMBER: 0001209191-22-042211 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220712 FILED AS OF DATE: 20220714 DATE AS OF CHANGE: 20220714 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Helash Kevin CENTRAL INDEX KEY: 0001818849 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36030 FILM NUMBER: 221084161 MAIL ADDRESS: STREET 1: C/O MARRONE BIO INNOVATIONS, INC. STREET 2: 1540 DREW AVENUE CITY: DAVIS STATE: CA ZIP: 95618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MARRONE BIO INNOVATIONS INC CENTRAL INDEX KEY: 0001441693 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 205137161 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7780-420 BRIER CREEK PARKWAY STREET 2: RALEIGH CITY: RALEIGH STATE: NC ZIP: 27617 BUSINESS PHONE: 530-750-2800 MAIL ADDRESS: STREET 1: 7780-420 BRIER CREEK PARKWAY STREET 2: RALEIGH CITY: RALEIGH STATE: NC ZIP: 27617 FORMER COMPANY: FORMER CONFORMED NAME: MARRONE ORGANICS INNOVATIONS INC DATE OF NAME CHANGE: 20080801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-12 1 0001441693 MARRONE BIO INNOVATIONS INC MBII 0001818849 Helash Kevin C/O MARRONE BIO INNOVATIONS, INC. 7780-420 BRIER CREEK PARKWAY RALEIGH NC 27617-7882 1 1 0 0 Chief Executive Officer Common Stock 2022-07-12 4 D 0 241568 0.00 D 0 D Stock Option (Right to Buy) 0.6321 2022-07-12 4 D 0 417273 0.00 D 2032-02-07 Common Stock 417273 0 D Stock Option (Right to Buy) 1.16 2022-07-12 4 D 0 2450000 0.00 D 2030-08-04 Common Stock 2450000 0 D Certain unvested restricted stock units became vested and all vested restricted stock units were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement") in exchange for 14,482 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 6,776 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX). This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 237,611 shares and replaced with an option to purchase 15,810 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 9,042 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. This option, which provided (1) with respect to 225,000 options, for vesting of 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 3, 2020, with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months; (2) with respect to 2,000,000 options, for vesting if/when performance milestone is attained; and (3) with respect to 225,000 options, for vesting over a period of four years as measured from the vesting commencement date of August 4, 2020, on a pro-rata basis equally each month, was assumed by BIOX in the Merger and replaced with an option to purchase 215,600 Ordinary Shares of BIOX for $13.18 per share. /s/ Linda V. Moore, as attorney in fact 2022-07-14